DRI Healthcare Reports Third-Quarter 2026 Results
Normalized Total Cash Receipts and Adjusted EBITDA each grew 9%, to $47.5 million and $40.0 million, respectively.
Normalized Total Cash Receipts and Adjusted EBITDA each grew 9%, to $47.5 million and $40.0 million, respectively.